Gastric Cancer Drugs Global Market Report 2025

Description

Gastric cancer drugs encompass anti-cancer medications administered either orally in the form of pills or through injection into a vein via an IV line or central venous catheter. This form of treatment proves effective for cancers that have metastasized to organs beyond their origin, as these medications travel through the bloodstream, reaching all parts of the body.

The primary types of gastric cancer drugs include doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. Sunitinib functions as both a chemotherapeutic agent and a receptor tyrosine kinase inhibitor, employed in the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumors (GIST). These drugs are administered via oral and parenteral routes and find application in hospitals, clinics, and other healthcare settings.

The gastric cancer drugs market research report is one of a series of new reports from The Business Research Company that provides gastric cancer drugs market statistics, including gastric cancer drugs industry global market size, regional shares, competitors with a gastric cancer drugs market share, detailed gastric cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer drugs industry. This gastric cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer drugs market size has grown rapidly in recent years. It will grow from $4.43 billion in 2024 to $5.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increase in pharmaceutical R&D expenditure, increased healthcare expenditure, strong economic growth in emerging markets and rapid growth in elderly population.

The gastric cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $7.6 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increase in gastric cancer incidence rate, strong pipeline of drugs, rise in acquisitions and partnerships, rise in healthcare expenditure, increasing geriatric population and revised FDA regulations to facilitate biologics drug development. Major trends in the forecast period include strategic collaborations and agreements to broaden product portfolios, collaborating and partnering with other companies or government bodies, increasing the number of pipeline studies to develop gastric cancer drugs, investing in AI solutions to reduced R&D costs, development of next-generation biologics and using CRISPR-cas9 technology in new drugs developments.

The rising incidence of obesity and the prevalence of smoking have contributed to an increase in the number of individuals suffering from gastric cancer. Tobacco use and unhealthy dietary habits significantly elevate the risk of developing stomach cancer. For example, in May 2023, the Government Digital Service, a UK-based government agency, projected that 25.9% of adults (18 years and older) in England were classified as obese in 2022, up from 25.2% the previous year. The growing number of gastric cancer cases is expected to drive the expansion of the gastric cancer drugs market.

The increasing global aging population is anticipated to further stimulate the growth of the gastric cancer drug market in the coming years. An aging population is characterized by a significant portion of a nation's or region's residents being older, typically 65 years and above. This trend arises from higher life expectancy and declining birth rates, leading to a larger elderly demographic relative to the overall population. Older patients often have reduced tolerance for certain cancer treatments, such as surgery or chemotherapy, creating a demand for more tailored treatment options, including specialized drugs that cater to their specific needs. For instance, in October 2022, the World Health Organization, a US-based specialized health agency, reported that by 2030, 1 in 6 people globally will be 60 or older, with the population in this age group expected to reach 2.1 billion by 2050. Consequently, the gastric cancer drug market is projected to grow in the future, driven by the expanding elderly population.

Many companies in the gastric cancer drugs market are innovating advanced products, including anti-PD-1 therapies, to enhance treatment effectiveness and improve patient outcomes. Anti-PD-1 therapy is a form of immunotherapy that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. For example, in November 2023, Merck & Co., Inc., a US-based pharmaceutical company, received approval from the Food and Drug Administration (FDA), a federal agency focused on protecting public health, for KEYTRUDA (pembrolizumab). This anti-PD-1 therapy is used to treat gastric cancer and is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is specifically for use in combination with trastuzumab, as well as fluoropyrimidine- and platinum-based chemotherapy. It received accelerated approval based on the tumor response rate and the duration of that response.

Numerous companies in the gastric cancer drugs market are concentrating on the development of innovative products, such as CLDN18.2-targeted treatments, to enhance therapy efficacy and provide more personalized options for patients. CLDN18.2-targeted treatment involves therapies designed to target claudin 18.2 (CLDN18.2), a protein primarily expressed in certain epithelial tissues, including the gastric epithelium. For instance, in October 2024, Astellas Pharma Inc., a Japan-based company, received FDA approval for VYLOY (zolbetuximab). VYLOY (zolbetuximab) is the first CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer with CLDN18.2-positive tumors. This treatment is administered alongside fluoropyrimidine- and platinum-based chemotherapy regimens and is indicated for adults with locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma.

In January 2023, Leap Therapeutics Inc., a US-based biotechnology company, acquired Flame Biosciences, Inc. for an undisclosed amount. This acquisition is intended to enhance Leap Therapeutics' oncology pipeline and expand its therapeutic offerings. It also enables Leap to incorporate Flame's clinical-stage anti-Claudin18.2 antibody, FL-301, which is being developed for gastric and pancreatic cancers, into its portfolio. Flame Biosciences Inc. is a US-based biotechnology firm focused on providing gastric cancer drugs.

Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratorios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The gastric cancer drugs market consists of sales of cyramza, docetaxel, and doxorubicin hydrochloride. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastric cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastric cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Imatinib, Trastuzumab, Other Types
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Clinics, Cancer Speciality Centers
Subsegments:
1) By Imatinib: Oral Formulations; Injectable Formulations; Combination Therapies
2) By Trastuzumab: Monotherapy; Combination Therapy With Chemotherapy; Biosimilars Of Trastuzumab
3) By Other Types: Chemotherapy Agents; Targeted Therapy Agents; Immunotherapy Agents; Supportive Care Medications
Companies Mentioned: F. Hoffmann-La Roche; Eli Lilly and Company; Otsuka Pharmaceutical; Jiangsu HengRui Medicine; Biocon
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25657

1. Executive Summary

2. Gastric Cancer Drugs Market Characteristics

3. Gastric Cancer Drugs Market Trends And Strategies

4. Gastric Cancer Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Gastric Cancer Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Gastric Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gastric Cancer Drugs Market Growth Rate Analysis
5.4. Global Gastric Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gastric Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gastric Cancer Drugs Total Addressable Market (TAM)

6. Gastric Cancer Drugs Market Segmentation

6.1. Global Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imatinib
Trastuzumab
Other Types
6.2. Global Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.3. Global Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Cancer Specialty Center
6.4. Global Gastric Cancer Drugs Market, Sub-Segmentation Of Imatinib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Formulations
Injectable Formulations
Combination Therapies
6.5. Global Gastric Cancer Drugs Market, Sub-Segmentation Of Trastuzumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy With Chemotherapy
Biosimilars Of Trastuzumab
6.6. Global Gastric Cancer Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy Agents
Targeted Therapy Agents
Immunotherapy Agents
Supportive Care Medications

7. Gastric Cancer Drugs Market Regional And Country Analysis

7.1. Global Gastric Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gastric Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastric Cancer Drugs Market

8.1. Asia-Pacific Gastric Cancer Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastric Cancer Drugs Market

9.1. China Gastric Cancer Drugs Market Overview
9.2. China Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastric Cancer Drugs Market

10.1. India Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastric Cancer Drugs Market

11.1. Japan Gastric Cancer Drugs Market Overview
11.2. Japan Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastric Cancer Drugs Market

12.1. Australia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastric Cancer Drugs Market

13.1. Indonesia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastric Cancer Drugs Market

14.1. South Korea Gastric Cancer Drugs Market Overview
14.2. South Korea Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastric Cancer Drugs Market

15.1. Western Europe Gastric Cancer Drugs Market Overview
15.2. Western Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastric Cancer Drugs Market

16.1. UK Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastric Cancer Drugs Market

17.1. Germany Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastric Cancer Drugs Market

18.1. France Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastric Cancer Drugs Market

19.1. Italy Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastric Cancer Drugs Market

20.1. Spain Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastric Cancer Drugs Market

21.1. Eastern Europe Gastric Cancer Drugs Market Overview
21.2. Eastern Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastric Cancer Drugs Market

22.1. Russia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastric Cancer Drugs Market

23.1. North America Gastric Cancer Drugs Market Overview
23.2. North America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastric Cancer Drugs Market

24.1. USA Gastric Cancer Drugs Market Overview
24.2. USA Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastric Cancer Drugs Market

25.1. Canada Gastric Cancer Drugs Market Overview
25.2. Canada Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastric Cancer Drugs Market

26.1. South America Gastric Cancer Drugs Market Overview
26.2. South America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastric Cancer Drugs Market

27.1. Brazil Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastric Cancer Drugs Market

28.1. Middle East Gastric Cancer Drugs Market Overview
28.2. Middle East Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastric Cancer Drugs Market

29.1. Africa Gastric Cancer Drugs Market Overview
29.2. Africa Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastric Cancer Drugs Market Competitive Landscape And Company Profiles

30.1. Gastric Cancer Drugs Market Competitive Landscape
30.2. Gastric Cancer Drugs Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Otsuka Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Jiangsu HengRui Medicine Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Biocon Overview, Products and Services, Strategy and Financial Analysis

31. Gastric Cancer Drugs Market Other Major And Innovative Companies

31.1. Sanofi
31.2. PV Pharma Healthcare (India)
31.3. Roche India
31.4. Novartis Oncology
31.5. Arlak Biotech (India)
31.6. Healthkind labs Pvt. Ltd.
31.7. SwisscheM Healthcare Pvt.Ltd
31.8. Apikos Pharma
31.9. Kolaz biotech.
31.10. CStone Pharma (China)
31.11. CARsgen Therapeutics (China)
31.12. JW Therapeutics (China)
31.13. BeiGene(China)
31.14. Takeda Pharmaceuticals (Japan)
31.15. Astellas Pharma Inc (Japan)

32. Global Gastric Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastric Cancer Drugs Market

34. Recent Developments In The Gastric Cancer Drugs Market

35. Gastric Cancer Drugs Market High Potential Countries, Segments and Strategies

35.1 Gastric Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Gastric Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Gastric Cancer Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer